CY1124194T1 - Διεργασια για την παρασκευη 6-(κυκλοπροπαναμιδο)-4-((2-μεθοξυ-3-(1-μεθυλ-1,2,4-τριαζολ-3-υλ)φαινυλ)αμινο-ν-(μεθυλ-d3)-πυριδαζιν-3-καρβοξαμιδιου - Google Patents

Διεργασια για την παρασκευη 6-(κυκλοπροπαναμιδο)-4-((2-μεθοξυ-3-(1-μεθυλ-1,2,4-τριαζολ-3-υλ)φαινυλ)αμινο-ν-(μεθυλ-d3)-πυριδαζιν-3-καρβοξαμιδιου

Info

Publication number
CY1124194T1
CY1124194T1 CY20211100374T CY211100374T CY1124194T1 CY 1124194 T1 CY1124194 T1 CY 1124194T1 CY 20211100374 T CY20211100374 T CY 20211100374T CY 211100374 T CY211100374 T CY 211100374T CY 1124194 T1 CY1124194 T1 CY 1124194T1
Authority
CY
Cyprus
Prior art keywords
methyl
triazol
pyridazine
carboxamide
methoxy
Prior art date
Application number
CY20211100374T
Other languages
Greek (el)
English (en)
Inventor
Ke Chen
Joerg Deerberg
Michael DUMMELDINGER
Bahar INANKUR
Sergei V. Kolotuchin
Jun Li
Amanda J. ROGERS
Victor W. Rosso
Eric M. SIMMONS
Maxime C. D SOUMEILLANT
Daniel S. Treitler
Jianji Wang
Bin Zheng
Michael J. Smith
Neil A. Strotman
Steven Tymonko
Tamas BENKOVICS
Dong Lin
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1124194T1 publication Critical patent/CY1124194T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/04—Mono-, di- or tri-methylamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/08—Preparation of carboxylic acid amides from amides by reaction at nitrogen atoms of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CY20211100374T 2017-03-30 2021-04-29 Διεργασια για την παρασκευη 6-(κυκλοπροπαναμιδο)-4-((2-μεθοξυ-3-(1-μεθυλ-1,2,4-τριαζολ-3-υλ)φαινυλ)αμινο-ν-(μεθυλ-d3)-πυριδαζιν-3-καρβοξαμιδιου CY1124194T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762478789P 2017-03-30 2017-03-30
PCT/US2018/025100 WO2018183649A1 (en) 2017-03-30 2018-03-29 Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide

Publications (1)

Publication Number Publication Date
CY1124194T1 true CY1124194T1 (el) 2022-05-27

Family

ID=62002470

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100374T CY1124194T1 (el) 2017-03-30 2021-04-29 Διεργασια για την παρασκευη 6-(κυκλοπροπαναμιδο)-4-((2-μεθοξυ-3-(1-μεθυλ-1,2,4-τριαζολ-3-υλ)φαινυλ)αμινο-ν-(μεθυλ-d3)-πυριδαζιν-3-καρβοξαμιδιου

Country Status (23)

Country Link
US (5) US20200239449A1 (https=)
EP (4) EP3601268B1 (https=)
JP (6) JP7113023B2 (https=)
KR (4) KR102642407B1 (https=)
CN (4) CN110475774B (https=)
AU (3) AU2018244451B2 (https=)
CA (2) CA3058209A1 (https=)
CY (1) CY1124194T1 (https=)
DK (1) DK3601268T3 (https=)
EA (2) EA201992308A1 (https=)
ES (2) ES2970229T3 (https=)
HR (1) HRP20210764T1 (https=)
HU (1) HUE054886T2 (https=)
IL (3) IL269586B (https=)
LT (1) LT3601268T (https=)
MX (4) MX2019011231A (https=)
PL (1) PL3601268T3 (https=)
PT (1) PT3601268T (https=)
RS (1) RS61816B1 (https=)
SG (2) SG11201909018VA (https=)
SI (1) SI3601268T1 (https=)
SM (1) SMT202100239T1 (https=)
WO (2) WO2018183656A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3495358T (lt) 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
JP7113023B2 (ja) * 2017-03-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
KR102848769B1 (ko) * 2018-05-31 2025-08-20 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태
CN115448910B (zh) * 2019-01-28 2024-04-19 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
US12570637B2 (en) 2019-06-12 2026-03-10 Bristol-Myers Squibb Company Crystalline salt forms 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide
JP7812785B2 (ja) 2019-09-18 2026-02-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｙｋ２阻害薬の剤形
CN114787152A (zh) * 2019-12-27 2022-07-22 苏州科睿思制药有限公司 一种bms-986165晶型及其制备方法和用途
WO2021143430A1 (zh) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型及其制备方法和用途
CN114787154A (zh) * 2020-01-19 2022-07-22 苏州科睿思制药有限公司 一种Deucravacitinib的晶型及其制备方法和用途
WO2021170046A1 (en) * 2020-02-26 2021-09-02 Beigene, Ltd. Tyk-2 inhibitor
CN113735836B (zh) * 2020-05-28 2023-05-30 江苏先声药业有限公司 哒嗪类化合物及其应用
CN113773262B (zh) * 2020-06-09 2024-08-09 江苏先声药业有限公司 哒嗪类化合物
KR20230042278A (ko) 2020-06-22 2023-03-28 베이진 엘티디 Tyk-2 저해제
CN115667246B (zh) * 2020-07-24 2024-08-23 上海翰森生物医药科技有限公司 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用
WO2022021684A1 (zh) * 2020-07-31 2022-02-03 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型csv及其制备方法和用途
IL301389A (en) 2020-09-18 2023-05-01 Bristol Myers Squibb Co Dosage forms for tyk2 inhibitors comprising swellable cores
WO2022083649A1 (zh) * 2020-10-20 2022-04-28 杭州领业医药科技有限公司 哒嗪衍生物的晶型
KR20230137962A (ko) * 2021-01-29 2023-10-05 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의 결정 형태
CN117377667A (zh) * 2021-03-29 2024-01-09 百时美施贵宝公司 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型
PE20250262A1 (es) 2021-05-14 2025-01-29 Bristol Myers Squibb Co Compuestos heterociclicos sustituidos
EP4387968B1 (en) 2021-08-20 2025-11-12 Bristol-Myers Squibb Company Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
EP4404930A1 (en) * 2021-09-23 2024-07-31 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
JP2024539703A (ja) 2021-10-28 2024-10-29 ブリストル－マイヤーズ スクイブ カンパニー デュークラバシチニブの局所製剤
EP4441043A1 (en) 2021-12-01 2024-10-09 Teva Czech Industries s.r.o Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates
US12222104B2 (en) * 2022-03-21 2025-02-11 General Electric Company Turbine engine combustor and combustor liner
WO2023181075A1 (en) * 2022-03-24 2023-09-28 Dr. Reddy's Laboratories Limited Amorphous solid dispersions of deucravacitinib and processes for the preparation thereof
CN114989103B (zh) * 2022-06-09 2024-07-09 杭州科巢生物科技有限公司 一种2-甲氧基-3-(1-甲基-1h-1,2,4-三唑-3-基)苯胺的制备方法
CN117447411B (zh) * 2022-07-18 2025-12-23 苏州鹏旭医药科技有限公司 一种杂环药物中间体的合成方法
WO2024017150A1 (zh) * 2022-07-18 2024-01-25 苏州鹏旭医药科技有限公司 一种氘可来昔替尼的合成方法
WO2024088282A1 (zh) * 2022-10-28 2024-05-02 浙江华海药业股份有限公司 一种哒嗪酰胺类化合物、其药物组合物及其作为tyk2抑制剂的用途
EP4713315A1 (en) * 2023-05-15 2026-03-25 Alivus Life Sciences Limited Process for the preparation of deucravacitinib, and crystalline forms thereof
EP4538259A1 (en) 2023-10-09 2025-04-16 Farmhispania Group, S.L. Processes for the preparation of deucravacitinib
WO2025131031A1 (zh) * 2023-12-22 2025-06-26 上海奥博生物医药股份有限公司 一种TyK2抑制剂及其中间体的制备方法
WO2025173029A1 (en) * 2024-02-14 2025-08-21 Natco Pharma Limited An improved process for the preparation of deucravacitinib
WO2025186427A1 (en) 2024-03-08 2025-09-12 Curia Spain, S.A.U. Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib
WO2025259267A1 (en) 2024-06-11 2025-12-18 Vector Vitale Ip Llc Pharmaceutical compositions for modulating inflammation and oxidative stress comprising chemically enriched elements
ES3059443A1 (es) 2024-09-17 2026-03-20 Moehs Iberica Sl Forma solida de 6-(ciclopropanocarboxamido)-4-((2-metoxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)piridazine-3-carboxilato de metilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de deucravacitinib

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6023649B2 (ja) 1976-09-08 1985-06-08 東ソー株式会社 臭化水素酸による臭化メチルの製造方法
JPS5455501A (en) 1977-10-05 1979-05-02 Toyo Soda Mfg Co Ltd Continuous preparation of methyl bromide
US4254061A (en) * 1979-09-11 1981-03-03 E. I. Du Pont De Nemours And Company Preparation of monomethylamine
ATE288420T1 (de) * 1999-06-09 2005-02-15 Yamanouchi Pharma Co Ltd Neuartige heterocyclische carboxamid-derivate
CN100579579C (zh) 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
CA2549385A1 (en) 2003-12-22 2005-07-21 Eli Lilly And Company Triazole, oxadiazole and thiadiazole derivative as ppar modulators for the treatment of diabetes
EP1931466B1 (de) * 2005-09-29 2012-11-14 Basf Se Formkörper enthaltend ein alumosilikat und aluminiumoxid und verfahren zur kontinuierlichen herstellung von methylaminen
KR20090111847A (ko) 2007-01-19 2009-10-27 아디아 바이오사이언스즈 인크. Ｍｅｋ 억제제
BR112012006956A2 (pt) * 2009-10-12 2015-09-15 Bayer Cropscience Ag 1- (pirida-3-il) -pirazóisol e 1- (pirimida-5-il) - pirazóisol como pesticidas
EP2542089B1 (en) * 2010-03-05 2017-01-18 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
CN102190616B (zh) * 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
JP5433087B2 (ja) * 2010-03-18 2014-03-05 ▲蘇▼州▲澤▼▲ジン▼生物制▲薬▼有限公司 重水素化メチルアミン及びその塩の製造方法
WO2013047813A1 (ja) 2011-09-30 2013-04-04 大鵬薬品工業株式会社 １，２，４－トリアジン－６－カルボキサミド誘導体
WO2013091011A1 (en) * 2011-12-21 2013-06-27 Biota Europe Ltd Heterocyclic urea compounds
CN104159891B (zh) 2012-01-10 2016-09-07 霍夫曼-拉罗奇有限公司 哒嗪酰胺化合物和它们作为syk 抑制剂的用途
WO2013171643A1 (en) 2012-05-14 2013-11-21 Piramal Enterprises Limited An improved process for preparation of irbesartan
LT3495358T (lt) * 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
KR102233252B1 (ko) * 2012-11-08 2021-03-26 브리스톨-마이어스 스큅 컴퍼니 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
JP7113023B2 (ja) * 2017-03-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
KR102848769B1 (ko) * 2018-05-31 2025-08-20 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태
JP7631193B2 (ja) * 2018-10-22 2025-02-18 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
KR20230137962A (ko) * 2021-01-29 2023-10-05 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의 결정 형태
CN117377667A (zh) * 2021-03-29 2024-01-09 百时美施贵宝公司 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型

Also Published As

Publication number Publication date
JP2024037836A (ja) 2024-03-19
WO2018183656A1 (en) 2018-10-04
MX2022010495A (es) 2022-09-21
US20210371404A1 (en) 2021-12-02
AU2018244451B2 (en) 2022-03-10
IL269594B1 (en) 2023-10-01
RS61816B1 (sr) 2021-06-30
JP7457758B2 (ja) 2024-03-28
US12545665B2 (en) 2026-02-10
LT3601268T (lt) 2021-05-25
EP4296258A3 (en) 2024-03-20
SG11201908947QA (en) 2019-10-30
CN116354939A (zh) 2023-06-30
EA201992300A1 (ru) 2020-02-20
AU2018244451A1 (en) 2019-11-21
MX2019011231A (es) 2019-11-18
EP3882237A2 (en) 2021-09-22
MX392693B (es) 2025-03-12
US12565487B2 (en) 2026-03-03
CN116813561A (zh) 2023-09-29
KR102642407B1 (ko) 2024-02-28
US20210107897A1 (en) 2021-04-15
EP4296258A2 (en) 2023-12-27
JP7837938B2 (ja) 2026-03-31
JP7476370B2 (ja) 2024-04-30
PL3601268T3 (pl) 2021-07-05
CA3058209A1 (en) 2018-10-04
JP2020512370A (ja) 2020-04-23
PT3601268T (pt) 2021-04-13
JP2020512380A (ja) 2020-04-23
KR102857398B1 (ko) 2025-09-08
KR20240154690A (ko) 2024-10-25
JP2023052683A (ja) 2023-04-11
CN110914260A (zh) 2020-03-24
JP7260481B2 (ja) 2023-04-18
IL269586A (en) 2019-11-28
CA3058177A1 (en) 2018-10-04
EP3601270A1 (en) 2020-02-05
US20200109134A1 (en) 2020-04-09
KR20190133725A (ko) 2019-12-03
MX2019011092A (es) 2020-01-20
US11649226B2 (en) 2023-05-16
US20230271946A1 (en) 2023-08-31
ES2970229T3 (es) 2024-05-27
CN110475774B (zh) 2023-06-02
IL269594B2 (en) 2024-02-01
EA201992308A1 (ru) 2020-02-13
SG11201909018VA (en) 2019-10-30
JP2022166011A (ja) 2022-11-01
AU2018244916A1 (en) 2019-11-21
EP3882237A3 (en) 2021-11-03
IL269586B (en) 2022-08-01
JP7113023B2 (ja) 2022-08-04
JP2026067880A (ja) 2026-04-21
WO2018183649A1 (en) 2018-10-04
SMT202100239T1 (it) 2021-05-07
ES2864450T3 (es) 2021-10-13
EP3882237B1 (en) 2023-12-20
AU2021261839A1 (en) 2021-12-02
EP3601268A1 (en) 2020-02-05
CN110475774A (zh) 2019-11-19
KR20250080914A (ko) 2025-06-05
DK3601268T3 (da) 2021-05-03
US10899745B2 (en) 2021-01-26
HUE054886T2 (hu) 2021-10-28
MX2022010496A (es) 2022-09-21
IL305615A (en) 2023-11-01
IL269594A (en) 2019-11-28
US20200239449A1 (en) 2020-07-30
BR112019020169A2 (pt) 2020-04-22
AU2021261839B2 (en) 2023-07-20
EP3601268B1 (en) 2021-03-17
AU2018244916B2 (en) 2021-11-18
SI3601268T1 (sl) 2021-07-30
KR20190133726A (ko) 2019-12-03
BR112019020163A2 (pt) 2020-04-22
HRP20210764T1 (hr) 2021-07-09
KR102720054B1 (ko) 2024-10-22

Similar Documents

Publication Publication Date Title
CY1124194T1 (el) Διεργασια για την παρασκευη 6-(κυκλοπροπαναμιδο)-4-((2-μεθοξυ-3-(1-μεθυλ-1,2,4-τριαζολ-3-υλ)φαινυλ)αμινο-ν-(μεθυλ-d3)-πυριδαζιν-3-καρβοξαμιδιου
CL2019001160A1 (es) 1,2,4–triazolonas 2,4,5–trisustituidas.
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
CY1125092T1 (el) Ιατρικη χρηση σχετικα με επεκταση τελομερους
ECSP21086530A (es) Derivados de ácido itacónico y usos de estos en el tratamiento de una enfermedad inflamatoria asociada con una respuesta inmunitaria indeseable
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
EA202090720A1 (ru) ПРОИЗВОДНЫЕ GalNAc
BR112017019287A2 (pt) composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
SA521422152B1 (ar) Vanin مركبات عطرية غير متجانسة كمثبطات
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
CY1122923T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
EA201390703A1 (ru) Замещенный натрий-1н-пиразол-5-олат
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
EA201990947A1 (ru) Замещенные производные 6-(1h-пиразол-1-ил)пиримидин-4-амина и их применение
CY1117577T1 (el) Υποκατεστημενα φουρανοκαρβοξαμιδια και χρηση αυτων
EA202092123A1 (ru) Антитела против клаудина 18.2 и их применения
MX385289B (es) Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk).
MX380776B (es) Derivados de pirazolilaminobenzimidazol como inhibidores de jak.
EA202091164A1 (ru) Производные кофейной кислоты и их применение
EA201991016A1 (ru) 2,4,5-трехзамещенные 1,2,4-триазолоны, применяемые в качестве ингибиторов дгодг
BR112021017710A2 (pt) Composto, composição farmacêutica, método de tratamento